# Adversarial verification verdict — dysembryoplastic_neuroepithelial_tumour.md

1. DOSE LEAK: none. Only digits in the file are "grade 1" (x2, WHO grade, not a dose) and "12th ed." in the source line. No mg / mg/m2 / AUC / Gy / numbered schedule anywhere.

2. UNGROUNDED CLAIMS: none found that are not uncontroversial guideline-standard.
   - Re-ran `grep -in "dysembryoplastic\|DNET\|DNT "` against devita.txt (15.9MB, confirmed 12th ed.) — zero hits, matching the draft agent's claim. This entity is genuinely absent from the DeVita text searched.
   - Re-ran `grep` for named drugs/trials (temozolomide, bevacizumab, vincristine, carboplatin, cisplatin, dabrafenib, trametinib, everolimus, FGFR, selumetinib, "trial", "randomized", "phase") — zero matches. The draft agent's stated omission (no regimen names, no FGFR1-inhibitor/targeted-therapy trial mentions, no numeric recurrence/malignant-transformation statistics) is confirmed correct; nothing was smuggled in despite the "omitted for lack of grounding" note.
   - Every clinical claim (surgical resection as definitive/curative treatment, epilepsy-surgery pathway, no role for chemo/RT, "very rarely" malignant transformation stated without a number, surveillance imaging as an alternative for stable/incidental lesions) is inline-tagged "(general oncology standard, not from DeVita's section on this disease)" and is consistent with well-established WHO-grade-1 glioneuronal tumour management — none of it reads as fabricated specificity.

3. CITATION: present. Closing "Sources:" line names NCCN Guidelines, WHO Classification of Tumours: CNS Tumours, and "DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th ed." with an explicit disclosure that DeVita was searched and has no dedicated section on this disease — no page numbers, name only, as required.

4. VERDICT: CLEAN (ready for R1). The sidecar is unusually honest for a disease with no DeVita coverage — it declined to invent regimens, trials, or statistics rather than fabricate grounding, and every claim is correctly flagged as general-standard rather than falsely attributed to DeVita.
